Cancer drug company Novogen Limited (ASX:NRT, NASDAQ:NVGN) has announced key new appointments in its transition into a clinical-stage company.
The dual ASX and NASDAQ-listed company has an investor base in Australia and the US and is growing its US presence.
Professor Peter Gunning, a leading researcher into children's cancer treatment and Ian Ross, an experienced multi-national pharmaceutical and biotechnology executive, will join Novogen's board in a non-executive capacity.
Industry expert David Gryska has 20 years of management experience across a number of US biotechnology companies. He will serve as strategic advisor to the board, with a focus on US expansion and liaison with US shareholders.
Novogen CEO Graham Kelly welcomed the new additions for their substantial biotechnology experience and business accumen. The company is seeking to develop two new drug platforms in treating cancer.
Novogen traded unchanged yesterday at 18 cents per share.
The company produced a net loss after tax of $785 thousand dollars for the half year ending June 30, 2013.
